Want to see HK:0455 full AI Analyst Report?
0455 Stock Chart & Stats
HK$0.13
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.13
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.08 - HK$0.14
Previous CloseN/A
Volume4.00K
Average Volume (3M)213.40K
Market Cap
HK$193.50M
Enterprise ValueHK$284.88M
Total Cash (Recent Filing)HK$64.81M
Total Debt (Recent Filing)HK$132.66M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.13%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding2,150,041,700
10 Day Avg. Volume322,600
30 Day Avg. Volume213,400
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.61
Price to Sales (P/S)0.86
P/FCF Ratio99.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate debt-to-equity indicates the company is not heavily burdened by borrowings, preserving some financial flexibility. This can support continued operations and selective investment while reducing the immediate balance-sheet pressure that typically accompanies elevated leverage.
Improved 2025 Cash GenerationThe return to positive operating and free cash flow in 2025 is a constructive sign for near-term funding capacity. If maintained, internally generated cash could reduce reliance on external financing and provide greater flexibility to support the pharmaceutical business.
Healthy Gross Margin BaseA gross margin around 41% provides an economically meaningful base from which operational improvements could eventually generate better earnings. The margin remains substantial for the industry, giving management room to pursue efficiency and restore profitability if revenue stabilizes.
Bears Say
Persistent Losses And Margin DeteriorationPersistent losses and sharply weaker net margins indicate that the current business model is not converting revenue into sustainable earnings. Continued operating losses can consume capital, restrict reinvestment, and make a durable recovery dependent on significant operational improvement.
Declining RevenueA shrinking revenue base limits the company’s ability to achieve operating leverage and absorb fixed costs. Unless sales recover, declining scale can keep profitability under pressure, reduce resources available for product investment, and weaken the foundation for durable earnings growth.
Volatile Cash Flow And Equity ErosionAlthough 2025 cash flow improved, the history of large swings and prior negative free cash flow shows that funding capacity remains inconsistent. Combined with declining equity, this raises the risk that ongoing losses could erode financial resilience and constrain future strategic choices.
Tianda Pharmaceuticals Ltd. News
0455 FAQ
What was Tianda Pharmaceuticals Ltd.’s price range in the past 12 months?
Tianda Pharmaceuticals Ltd. lowest stock price was HK$0.08 and its highest was HK$0.14 in the past 12 months.
What is Tianda Pharmaceuticals Ltd.’s market cap?
Tianda Pharmaceuticals Ltd.’s market cap is HK$193.50M.
When is Tianda Pharmaceuticals Ltd.’s upcoming earnings report date?
Tianda Pharmaceuticals Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 156 days.
How were Tianda Pharmaceuticals Ltd.’s earnings last quarter?
Tianda Pharmaceuticals Ltd. released its earnings results on Aug 10, 2026. The company reported -HK$0.015 earnings per share for the quarter.
Is Tianda Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Tianda Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Tianda Pharmaceuticals Ltd. pay dividends?
Tianda Pharmaceuticals Ltd. pays a Annually dividend of HK$0.003 which represents an annual dividend yield of 1.13%. See more information on Tianda Pharmaceuticals Ltd. dividends here
What is Tianda Pharmaceuticals Ltd.’s EPS estimate?
Tianda Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianda Pharmaceuticals Ltd. have?
Tianda Pharmaceuticals Ltd. has 2,150,041,700 shares outstanding.
What happened to Tianda Pharmaceuticals Ltd.’s price movement after its last earnings report?
Tianda Pharmaceuticals Ltd. reported an EPS of -HK$0.015 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tianda Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:0455
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tianda Pharmaceuticals Ltd.
Founded in 1992 and headquartered in Central, Hong Kong, Tianda Pharmaceuticals Limited operates as an investment holding company and a subsidiary of Tianda Group Limited. The firm, which changed its name from Tianda Holdings Limited in September 2012, focuses on the research, development, manufacturing, and distribution of a wide array of pharmaceutical, biotechnology, and healthcare products. Its commercial reach extends across Mainland China, Hong Kong, and Australia. The company's diverse portfolio includes traditional Chinese medicines, chemical drugs, biological products, and medical appliances. These offerings target numerous therapeutic areas, such as cardio-cerebrovascular health, pediatric care, anti-flu and respiratory conditions, anti-infection, detoxification, and urological disorders. Health supplements are specifically marketed under the "Herb Valley" and "Tuokang" brand names. Furthermore, Tianda Pharmaceuticals is involved in the wholesale and retail of Chinese herbal medicines, traditional Chinese medicine (TCM) decoction pieces, and other Chinese medicinal products, provides Chinese medical services, and trades agricultural by-products.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―